The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

JP Morgan reported in their recent outlook piece that "The backdrop for the European consumer is also improving. Real wages ...

GSK plc recently received approval from the U.S. Food and Drug Administration (FDA) for a prefilled syringe version of SHINGRIX, the company’s vaccine for shingles (herpes zoster). The ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Xelix, a leading agentic AI software company in the Accounts Payable (AP) space, today announced a $160 million Series B ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

The Global Bladder Cancer Market was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 7.2 Billion by 2035, ...

Xelix has raised $160m in a Series B to accelerate AI-driven innovation in accounts payable and expand globally.